Reference

1. Shared decision-making for vitiligo. Br J Dermatol. 2021 Oct;185(4):e158–78. 
2. Lucy Y. Liu, James P. Strassner,Maggi A. Refat, MD,John E. Harris, MD, PhD, and Brett A. King, MD P. Repigmentation in vitiligo using the janus kinase inhibitor, tofacitinib, may require concomitant light exposure. Physiol Behav. 2017;176(1):675–82. 
3. Jacobsen KH, Hay MC, Manske J, Waggett CE. Curricular models and learning objectives for undergraduate minors in global health. Ann Glob Heal. 2020;86(1):1–9. 
4. Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: A comprehensive overview: Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol [Internet]. 2011;65(3):473–91. Available from: http://dx.doi.org/10.1016/j.jaad.2010.11.061
5. Boza JC, Fabbrin A, Cestari TF. Translation, cross-cultural adaptation and validation of the vitiligo-speci fi c health-related quality of life instrument. :358–62. 
6. Dolatshahi M, Ghazi P, Feizy V, Hemami M. Life quality assessment among patients with vitiligo: Comparison of married and single patients in Iran. Indian J Dermatol Venereol Leprol. 2008;74(6):700. 
7. Gawkrodger DJ, Ormerod AD, Shaw L, Mauri-Sole I, Whitton ME, Watts MJ, et al. Guideline for the diagnosis and management of vitiligo. Br J Dermatol. 2008;159(5):1051–76. 
8. Borimnejad L, Parsa Yekta Z, Nikbakht-Nasrabadi A, Firooz A. Quality of life with vitiligo: Comparison of male and female muslim patients in Iran. Gend Med. 2006;3(2):124–30. 
9. Lotti T, Buggiani G, Troiano M, Assad GB, Delescluse J, De Giorgi V, et al. Targeted and combination treatments for vitiligo: Comparative evaluation of different current modalities in 458 subjects. Dermatol Ther. 2008;21(SUPPL. 1):20–6. 
10. Lotti T, Agarwal K, Podder I, Satolli F, Kassir M, Schwartz RA, et al. Safety of the current drug treatments for vitiligo. Expert Opin Drug Saf [Internet]. 2020;19(4):499–511. Available from: https://doi.org/10.1080/14740338.2020.1729737
11. Jowett S, Ryan T. Skin disease and handicap: An analysis of the impact of skin conditions. Soc Sci Med. 1985;20(4):425–9. 
12. AL-smadi K, Imran M, Leite-Silva VR, Mohammed Y. Vitiligo: A Review of Aetiology, Pathogenesis, Treatment, and Psychosocial Impact. Cosmetics. 2023;10(3):84. 
13. Halder RM, Chappell JL. Vitiligo Update. Semin Cutan Med Surg [Internet]. 2009;28(2):86–92. Available from: http://dx.doi.org/10.1016/j.sder.2009.04.008
14. Henning SW, Jaishankar D, Barse LW, Dellacecca ER, Lancki N, Webb K, et al. The relationship between stress and vitiligo: Evaluating perceived stress and electronic medical record data. PLoS One [Internet]. 2020;15(1):1–14. Available from: http://dx.doi.org/10.1371/journal.pone.0227909
15. Rahman R, Hasija Y. Exploring vitiligo susceptibility and management?: a brief review. 2018;1–13. 
16. Mehdi Rashighi, MD and John E. Harris, MD P. Vitiligo pathogenesis and emerging treatments. Physiol Behav. 2016;257–65. 
17. Rashighi M, Harris JE. Vitiligo Pathogenesis and Emerging Treatments. Dermatol Clin [Internet]. 2017;35(2):257–65. Available from: http://dx.doi.org/10.1016/j.det.2016.11.014
18. Rajatanavin N, Suwanachote S, Kulkollakarn S. Dihydroxyacetone: A safe camouflaging option in vitiligo. Int J Dermatol. 2008;47(4):402–6. 
19. Mehta H, Kumar S, Parsad D, Bishnoi A, Vinay K, Kumaran MS. Oral cyclosporine is effective in stabilizing active vitiligo: Results of a randomized controlled trial. Dermatol Ther. 2021;34(5). 
20. Craiglow BG, King BA. Tofacitinib citrate for the treatment of Vitiligo a pathogenesis-directed therapy. JAMA Dermatology. 2015;151(10):1110–2. 
21. ALI ESMAIL AL-SNAFI. Chemical Constituents and Pharmacological Activities of Lantana Camara – a Review. Asian J Pharm Clin Res. 2019;10–20. 
22. Radmanesh M, Saedi K. The efficacy of combined PUVA and low-dose azathioprine for early and enhanced repigmentation in vitiligo patients. J Dermatolog Treat. 2006;17(3):151–3. 
23. Abdelmaksoud A, Dave DD, Lotti T, Vestita M. Topical methotrexate 1% gel for treatment of vitiligo: A case report and review of the literature. Dermatol Ther. 2019;32(5):2–5. 
24. Uppal SK, Kearns DG, Chat VS, Wu JJ. Ruxolitinib cream for the treatment of vitiligo. Lancet [Internet]. 2020;396(10264):1735–6. Available from: http://dx.doi.org/10.1016/S0140-6736(20)32469-7
25. Parsad D, Kanwar A. Oral minocycline in the treatment of vitiligo - A preliminary study. Dermatol Ther. 2010;23(3):305–7. 
26. Radakovic-Fijan S, Fürnsinn-Friedl AM, Hönigsmann H, Tanew A. Oral dexamethasone pulse treatment for vitiligo. J Am Acad Dermatol. 2001;44(5):814–7. 
27. Davinder Parsad, Roma Pandhi, Sunil Dogra  and BK. Topical prostaglandin analog (PGE 2 ) in vitiligo – a preliminary study. Int J Dermatol. 2002;41:942–5. 
28. Aleksandra Vojvodic, Priyanka Karagaiah, Yan Valle, Julia Sigova, Nicola Zerbinati, Petar Vojvodic, Davinder Parsad, Robert A. Schwaertz, Stephan Grabbe MG& TL. Emerging drugs for the treatment of vitiligo. Expert Opin Emerg Drugs [Internet]. 2020;25(1):7–24. Available from: https://doi.org/10.1080/14728214.2020.1712358
29. ?endur N, Karaman G, Saniç N, ?avk E. Topical pimecrolimus: A new horizon for vitiligo treatment? J Dermatolog Treat. 2006 Dec;17(6):338–42. 
30. Hasan R, Agarwal K, Podder I, Misitzis A, Schwartz RA, Wollina U, et al. Simvastatin in vitiligo: an update with recent review of the literature. Int J Dermatol. 2021;60(10):e390–6. 
31. Chiavérini C, Passeron T, Ortonne JP. Treatment of vitiligo by topical calcipotriol. 2002.
32. Sisti A, Sisti G, Oranges CM. Effectiveness and safety of topical tacrolimus monotherapy for repigmentation in vitiligo: A comprehensive literature review. An Bras Dermatol. 2016;91(2):187–95. 
33. Rashighi M, Harris JE. Vitiligo Pathogenesis and Emerging Treatments. Dermatol Clin. 2017 Apr;35(2):257–65. 
34. Manga P, Elbuluk N, Orlow SJ. Recent advances in understanding vitiligo [version 1; referees: 3 approved]. F1000Research. 2016;5(0):1–9. 
35. Alicja Fr ?aczek, Marta Kasprowicz-Furma ´nczyk WP and AOS. Surgical treatment of vitiligo. Dermatologic Surg. 1999;25(8):669. 
36. Agarwal K, Podder I, Kassir M, Vojvodic A, Schwartz RA, Wollina U, et al. Therapeutic options in vitiligo with special emphasis on immunomodulators: A comprehensive update with review of literature. Dermatol Ther. 2020;33(2):1–14. 
37. Cichorek M, Wachulska M, Stasiewicz A, Tymi?ska A. Skin melanocytes: Biology and development. Postep Dermatologii i Alergol. 2013;30(1):30–41. 
38. Slominski A, Wortsman J, Plonka PM, Schallreuter KU, Paus R, Tobin DJ. Hair follicle pigmentation. J Invest Dermatol. 2005;124(1):13–21. 
39. Bae JM, Jung HM, Hong BY, Lee JH, Choi WJ, Lee JH, et al. Phototherapy for Vitiligo: A Systematic Review and Meta-analysis. JAMA dermatology. 2017 Jul;153(7):666–74. 
40. Palmer BC, DeLouise LA. Nanoparticle-Enabled Transdermal Drug Delivery Systems for Enhanced Dose Control  and Tissue Targeting. Molecules. 2016 Dec;21(12). 
41. Marwah H, Garg T, Goyal AK, Rath G. Permeation enhancer strategies in transdermal drug delivery. Drug Deliv. 2016;23(2):564–78. 
42. Sun MC, Xu XL, Lou XF, Du YZ. Recent Progress and Future Directions: The Nano-Drug Delivery System for the  Treatment of Vitiligo. Int J Nanomedicine. 2020;15:3267–79. 
43. Das S, Kaur S. Nano-Lipid-Carriers for the Treatment of Vitiligo: A Recent Update,  Pathophysiology and Mechanism of Drug Delivery. Curr Mol Pharmacol. 2021;14(3):306–20. 
44. Baidya S, Dey P, Mohanty R. Assessment of quality of life in vitiligo patients attending a tertiary care  hospital - A cross sectional study. Ind Psychiatry J. 2021;30(1):62–6. 
45. Grimes PE, Miller MM. Vitiligo: Patient stories, self-esteem, and the psychological burden of disease. Int J Women’s Dermatology [Internet]. 2018;4(1):32–7. Available from: https://doi.org/10.1016/j.ijwd.2017.11.005
46. Saeedinezhad F, Firouzkouhi M, Abdollahimohammad A, Rahnama M. The challenges facing with vitiligo: a phenomenological research. Int J Pharm Res Allied Sci. 2016;5(3):356–64. 
47. Mishra N, Rastogi MK, Gahalaut P, Agrawal S. Dermatology specific quality of life in vitiligo patients and its relation with various variables: A hospital based crosssectional study. J Clin Diagnostic Res. 2014;8(6):18–20. 
48. Mattoo SK, Handa S, Kaur I, Gupta N, Malhotra R. Psychiatric morbidity in vitiligo: Prevalence and correlates in India. J Eur Acad Dermatology Venereol. 2002;16(6):573–8. 
49. Pahwa P, Mehta M, Khaitan BK, Sharma VK, Ramam M. The psychosocial impact of vitiligo in Indian patients. Indian J Dermatol Venereol Leprol. 2013;79(5):679–85. 
50. Ezzedine K, Eleftheriadou V, Jones H, Bibeau K, Kuo FI, Sturm D, et al. Psychosocial Effects of Vitiligo: A Systematic Literature Review. Am J Clin Dermatol [Internet]. 2021;22(6):757–74. Available from: https://doi.org/10.1007/s40257-021-00631-6